{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:18:28Z","timestamp":1792685908732,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neurot.2025.e00760","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T02:58:43Z","timestamp":1759633123000},"page":"e00760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence of hypogammaglobulinemia after non-anti-CD20 therapies and impact of switching to rituximab\/ocrelizumab in multiple sclerosis"],"prefix":"10.1016","volume":"22","author":[{"given":"Marine","family":"Perriguey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Rigollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Graille-Avy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Lafontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lemarchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tifanie","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Demorti\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Boutiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Hil\u00e9zian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Durozard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Maarouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Z\u00e9phir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Audoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neurot.2025.e00760_bib1","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1212\/NXI.0000000000001115","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab","volume":"9","author":"Perriguey","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00760_bib2","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, Rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00760_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of Immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00760_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00415-025-13133-w","article-title":"Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis","volume":"272","author":"Davies","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00760_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231162661","article-title":"The impact of disease-modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis: a retrospective cross-sectional study","volume":"16","author":"Klein","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2025.e00760_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00760_bib7","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1177\/1352458513477229","article-title":"Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients","volume":"19","author":"Selter","year":"2013","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00760_bib8","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s13311-023-01446-5","article-title":"Assessing sustained B-Cell depletion and disease activity in a French multiple sclerosis cohort treated by long-term IV Anti-CD20 antibody therapy","volume":"20","author":"Freeman","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurot.2025.e00760_bib9","article-title":"Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: a Swedish cohort study","volume":"25","author":"Hallberg","year":"2024","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00760_bib10","first-page":"1330","article-title":"Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis","volume":"93","author":"Zhu","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00760_bib11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaneurol.2023.1542","article-title":"Comparison between Dimethyl Fumarate, fingolimod, and Ocrelizumab after Natalizumab cessation","volume":"80","author":"Zhu","year":"2023","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00760_bib12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s13311-020-00975-7","article-title":"Differential effects of fingolimod and natalizumab on B cell repertoires in multiple sclerosis patients","volume":"18","author":"Kowarik","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00760_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235449","article-title":"Differential effects of disease modifying drugs on peripheral blood B cell subsets: a cross sectional study in multiple sclerosis patients treated with interferon-\u03b2, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab","volume":"15","author":"Kemmerer","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00760_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228380","article-title":"Treatment effects of fingolimod in multiple sclerosis: selective changes in peripheral blood lymphocyte subsets","volume":"15","author":"Hjorth","year":"2020","journal-title":"PLoS One"},{"issue":"5566","key":"10.1016\/j.neurot.2025.e00760_bib15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists","volume":"296","author":"Mandala","year":"2002","journal-title":"Science"},{"issue":"6972","key":"10.1016\/j.neurot.2025.e00760_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2025.e00760_bib17","doi-asserted-by":"crossref","first-page":"102987","DOI":"10.1016\/j.msard.2021.102987","article-title":"Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis","volume":"52","author":"Cuculiza Henriksen","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00760_bib18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/1352458514556296","article-title":"Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF","volume":"21","author":"Warnke","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00760_bib19","article-title":"De-escalating and discontinuing disease-modifying therapies in multiple sclerosis","author":"Androdias","year":"2024","journal-title":"Brain"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:35:07Z","timestamp":1763638507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925002387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1878747925002387"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00760","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of hypogammaglobulinemia after non-anti-CD20 therapies and impact of switching to rituximab\/ocrelizumab in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00760"}}